Celldex Therapeutics Inc

24.08.2026 г., 20:06 ч. UTC

Celldex Therapeutics is trading higher, reflecting positive sentiment in the biotechnology sector despite no specific company news. Overall movement remains higher since Friday's close.

21.08.2026 г., 19:26 ч. UTC

Celldex Therapeutics Inc. shares are higher, maintaining above the 20-day moving average amid a broader market rebound and shifts toward safe-haven assets.

20.08.2026 г., 20:01 ч. UTC

Celldex Therapeutics shares are lower as biotechnology stocks face pressure, reflecting a notable decline since Wednesday. Earlier, shares briefly peaked before dropping sharply.

19.08.2026 г., 19:26 ч. UTC

Celldex Therapeutics Inc is trading higher during Wednesday's session, maintaining gains since Tuesday's close despite earlier intraday fluctuations.

18.08.2026 г., 19:36 ч. UTC

Celldex Therapeutics Inc. shares are lower today amid broader market concerns, including rising treasury yields and inflation fears, despite remaining above the 20-day moving average.

17.08.2026 г., 19:16 ч. UTC

Celldex Therapeutics Inc. shares are lower today, retracing from earlier gains amid broader market concerns over economic growth following recent U.S. retail sales data.

14.08.2026 г., 20:06 ч. UTC

Celldex Therapeutics Inc shares are lower today amid mixed market sentiment following a decline in U.S. retail sales for July.

13.08.2026 г., 20:06 ч. UTC

Celldex Therapeutics shares are lower today, continuing a decline since Wednesday amid rising initial jobless claims in the U.S.

12.08.2026 г., 19:56 ч. UTC

Celldex Therapeutics Inc is higher today, maintaining a positive trend after closing up in the last seven sessions. The stock pulled back slightly from an earlier peak.

11.08.2026 г., 20:06 ч. UTC

Celldex Therapeutics Inc shares are higher today, marking six consecutive sessions of gains. The stock remains significantly above its 20-day moving average.

10.08.2026 г., 19:16 ч. UTC

Celldex Therapeutics shares are higher as Barclays and Morgan Stanley raise price targets to $53.00 and $46.00, respectively, maintaining overweight ratings.

7.08.2026 г., 19:11 ч. UTC

Celldex Therapeutics shares are lower despite Morgan Stanley and Barclays raising price targets to $46 and $53, respectively. Broader market volatility persists.

5.08.2026 г., 20:01 ч. UTC

Celldex Therapeutics Inc shares are trading higher amid a positive market backdrop, supported by declining oil prices and optimism over U.S.-Iran negotiations.

4.08.2026 г., 19:56 ч. UTC

Celldex Therapeutics Inc shares are higher today, supported by overall market strength amid a decline in crude oil prices. No specific company news was identified.

3.08.2026 г., 19:53 ч. UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31.07.2026 г., 19:36 ч. UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30.07.2026 г., 18:51 ч. UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29.07.2026 г., 20:03 ч. UTC

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28.07.2026 г., 19:36 ч. UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27.07.2026 г., 19:31 ч. UTC

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22.07.2026 г., 20:01 ч. UTC

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21.07.2026 г., 23:01 ч. UTC

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.